Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideo Okonogi is active.

Publication


Featured researches published by Hideo Okonogi.


Nephrology Dialysis Transplantation | 2014

A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy

Tetsuya Kawamura; Mitsuhiro Yoshimura; Yoichi Miyazaki; Hidekazu Okamoto; Kenjiro Kimura; Keita Hirano; Masato Matsushima; Yasunori Utsunomiya; Makoto Ogura; Takashi Yokoo; Hideo Okonogi; Takeo Ishii; Akihiko Hamaguchi; Hiroyuki Ueda; Akira Furusu; Satoshi Horikoshi; Yusuke Suzuki; Takanori Shibata; Takashi Yasuda; Sayuri Shirai; Toshiyuki Imasawa; Koichi Kanozawa; Akira Wada; Izumi Yamaji; Naoto Miura; Hirokazu Imai; Kenji Kasai; Jun Soma; Shouichi Fujimoto; Seiichi Matsuo

Background The study aim was, for the first time, to conduct a multicenter randomized controlled trial to evaluate the effect of tonsillectomy in patients with IgA nephropathy (IgAN). Methods Patients with biopsy-proven IgAN, proteinuria and low serum creatinine were randomly allocated to receive tonsillectomy combined with steroid pulses (Group A; n = 33) or steroid pulses alone (Group B; n = 39). The primary end points were urinary protein excretion and the disappearance of proteinuria and/or hematuria. Results During 12 months from baseline, the percentage decrease in urinary protein excretion was significantly larger in Group A than that in Group B (P < 0.05). However, the frequency of the disappearance of proteinuria, hematuria, or both (clinical remission) at 12 months was not statistically different between the groups. Logistic regression analyses revealed the assigned treatment was a significant, independent factor contributing to the disappearance of proteinuria (odds ratio 2.98, 95% CI 1.01–8.83, P = 0.049), but did not identify an independent factor in achieving the disappearance of hematuria or clinical remission. Conclusions The results indicate tonsillectomy combined with steroid pulse therapy has no beneficial effect over steroid pulses alone to attenuate hematuria and to increase the incidence of clinical remission. Although the antiproteinuric effect was significantly greater in combined therapy, the difference was marginal, and its impact on the renal functional outcome remains to be clarified.


Journal of Nephrology | 2013

A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease

Tetsuya Kawamura; Kensuke Joh; Hideo Okonogi; Kentaro Koike; Yasunori Utsunomiya; Yoichi Miyazaki; Masato Matsushima; Mitsuhiro Yoshimura; Satoshi Horikoshi; Yusuke Suzuki; Akira Furusu; Takashi Yasuda; Sayuri Shirai; Takanori Shibata; Masayuki Endoh; Motoshi Hattori; Ritsuko Katafuchi; Akinori Hashiguchi; Kenjiro Kimura; Seiichi Matsuo; Yasuhiko Tomino

BACKGROUND A multicenter case-control study on IgA nephropathy (IgAN) was conducted to develop an evidence-based clinicopathologic classification of IgAN for predicting long-term renal outcome. METHODS Two hundred and eighty-seven patients including those with isolated hematuria or very mild proteinuria were enrolled. During a median follow-up of 9.3 years after biopsy, 49 patients (17%) progressed to end stage renal disease (ESRD). The associations between pathological variables and the need for chronic dialysis was examined by multivariate logistic regression analysis separately in patients who required dialysis earlier than 5 years (Early Progressors) and those who required dialysis within 5 to 10 years (Late Progressors) after biopsy. RESULTS Independent pathological variables predicting progression to ESRD were global sclerosis, segmental sclerosis and fibrous crescents for Early Progressors, and global sclerosis and cellular/fibrocellular crescents for Late Progressors. Four histological grades, HG 1, HG 2, HG 3 and HG 4, were established corresponding to <25%, 25-49%, 50-74% and =75% of glomeruli exhibiting cellular or fibrocellular crescents, global sclerosis, segmental sclerosis or fibrous crescents. Eleven (7%) patients in HG 1, 12 (16%) in HG 2, 13 (31%) in HG 3 and 13 (68%) in HG 4 progressed to ESRD. Multivariate logistic analysis revealed that the risk of progression to ESRD was significantly higher in HG 2, 3 and 4 than in HG 1 (odds ratio, 2.4, 5.7 and 27.6 vs. 1.0). CONCLUSIONS Our evidence-based histologic classification can identify the magnitude of the risk of progression to ESRD and is useful for predicting long-term renal outcome in IgAN.


Clinical Journal of The American Society of Nephrology | 2010

Glomerular Density in Renal Biopsy Specimens Predicts the Long-Term Prognosis of IgA Nephropathy

Nobuo Tsuboi; Tetsuya Kawamura; Kentaro Koike; Hideo Okonogi; Keita Hirano; Akihiko Hamaguchi; Yoichi Miyazaki; Makoto Ogura; Kensuke Joh; Yasunori Utsunomiya; Tatsuo Hosoya

BACKGROUND AND OBJECTIVES An early histopathologic predictor of the renal prognosis, before the occurrence of advanced glomerular sclerosis/interstitial fibrosis and/or apparent renal dysfunction, remains to be established in IgA nephropathy (IgAN). This study aimed to determine whether the glomerular density (GD; nonsclerotic glomerular number per renal cortical area) of biopsy specimens obtained at an early stage of IgAN could predict the long-term renal outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The predictive value of the factors at biopsy, including the GD, on the renal outcome was retrospectively analyzed for 98 patients who had IgAN with an estimated GFR of > or =60 ml/min per 1.73 m(2) at biopsy (87 ml/min per 1.73 m(2) on average). RESULTS The individual value of GD in biopsy ranged from 1.2 to 8.1/mm(2) (i.e., approximately a seven-fold variation), and the GD showed a close inverse correlation with mean glomerular volume. Among the various clinicopathologic factors involved, both a cellular/fibrocellular crescent and the GD were found to be significant predictors of progression in multivariate analyses. A low GD in the biopsy specimens was frequently associated with a steeper slope of the renal function and a synergistically enhanced risk for progression with the presence of cellular/fibrocellular crescent. The renal function, proteinuria, degrees of glomerulosclerosis, and interstitial fibrosis at biopsy were not independent predictors of the prognosis in these patients. CONCLUSIONS A strong predictive relationship of low GD with progression observed in this study suggests that GD may serve as an early histopathologic marker of long-term renal prognosis in IgAN.


Cancer Letters | 1997

Induction of aberrant crypt foci in C57BL/6N mice by 2-amino-9H-pyrido [2,3-b]indole (AαC) and 2-amino-3,8-dimethylimidazo [4,5-f]quinoxaline (MeIQx)

Hideo Okonogi; Toshikazu Ushijima; Hidesuke Shimizu; Takashi Sugimura; Minako Nagao

The inductions of aberrant crypt foci (ACF) by two carcinogenic heterocyclic amines (HCAs), 2-amino-9H-pyrido[2,3-b]indole (A alphaC) and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), were studied in the large intestine of C57BL/6N mice. Seven-week-old mice were fed a diet supplemented with 500 or 800 ppm of A alphaC, or 400 or 600 ppm of MeIQx for 7 weeks, followed by a basal diet for another 7 weeks. A alphaC at 800 ppm induced 8.0 +/- 1.9 and 7.8 +/- 2.5 ACF in female and male mice, respectively. MeIQx at 600 ppm induced 2.8 +/- 1.8 and 1.6 +/- 0.8 ACF in females and males, respectively. At lower concentrations of A alphaC and MeIQx, many fewer ACF were induced. No ACF were induced in the control group. The size of ACF (number of aberrant crypts/ACF) in all experimental groups was between 1.0 and 1.5. More than half the A alphaC-induced ACF were located in the region about 20-40% of the distance from the ileocecal portion to the anus. Although both of these HCAs were reported to induce tumors in the liver and other organs, but not in the large intestine, of CDF1 mice, these findings suggest that both these HCAs, and especially A alphaC, induce large intestinal tumors in C57BL/6N mice.


Archives of Toxicology | 1996

Metallothionein content increased in the liver of mice exposed to magnetic fields

Masahiko Satoh; Yoko Tsuji; Yuzo Watanabe; Hideo Okonogi; Yuji Suzuki; Masayoshi Nakagawa; Hidesuke Shimizu

Abstract Although recent studies have shown that various stress can induce metallothionein (MT) synthesis in animal tissues, the induction of MT synthesis by exposure to static magnetic fields (SMF) has not been reported. We measured MT levels in the liver, kidney and brain of mice exposed to SMF and also evaluated the effect of SMF exposure on the induction of hepatic MT by treatment with carbon tetrachloride (CCl4). The MT content in the liver was significantly increased by exposure to 4.7 T of SMF for 6, 24, or 48 h, whereas that in the kidney or brain was not changed compared to the control. The combination of CCl4 injection and SMF exposure induced elevation of the hepatic MT content exceeding that induced by either treatment alone. These results indicate that exposure to the strong SMF induces MT synthesis in the liver in mice and enhances the hepatic MT synthesis induced by CCl4 administration.


Journal of the Renin-Angiotensin-Aldosterone System | 2012

The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease

Nobuo Tsuboi; Tetsuya Kawamura; Hideo Okonogi; Takeo Ishii; Tatsuo Hosoya

Introduction: There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD). Methods: This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin–angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25–50 mg/day) were investigated for 12 months. Results: Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline. Conclusion: The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors.


Clinical Nephrology | 2013

Factors related to the glomerular size in renal biopsies of chronic kidney disease patients.

Nobuo Tsuboi; Yasunori Utsunomiya; Kentaro Koike; Go Kanzaki; Keita Hirano; Hideo Okonogi; Yoich Miyazaki; Makoto Ogura; Kensuke Joh; Tetsuya Kawamura; Tatsuo Hosoya

BACKGROUND Glomerular enlargement is an important process that preserves the optimal surface area of glomerular capillaries under both physiological and pathological conditions. However, information is limited regarding how the glomerular size is defined, especially in chronic kidney disease (CKD) patients. METHODS A total of 206 renal biopsy specimens obtained from two different patient cohorts with or without a diagnosis of glomerulonephritis (non-GN group and IgAN group) were examined. The mean glomerular volume was estimated from the outer capillary area of individual glomeruli, and the clinicopathological factors at biopsy that were associated with the mean glomerular volume were analyzed in each group. RESULTS The mean glomerular volume showed maximal 5.8 and 7.9-fold variations between individuals in the non-GN and IgAN groups, respectively. In both groups, the body mass index and glomerular density (non-sclerotic glomerular number per renal cortical area of the biopsy) were consistently identified as independent factors that were associated with the mean glomerular volume. In addition, the multivariate analyses using the glomerular density/body mass index ratio showed a more close association with the mean glomerular volume than the analyses using each measure separately. CONCLUSION These results suggest that factors presumably reflecting both body consumption and nephron number have close relationships with the glomerular size, regardless of mechanism(s) underlying the injury. The most relevant factor affecting glomerular size may be a balance between these two measures.


Nephron Clinical Practice | 2011

A Predictive Clinical Grading System for Immunoglobulin A Nephropathy by Combining Proteinuria and Estimated Glomerular Filtration Rate

Hideo Okonogi; Yasunori Utsunomiya; Yoichi Miyazaki; Kentarou Koike; Keita Hirano; Nobuo Tsuboi; Takahide Suzuki; Yoriko Hara; Makoto Ogura; Tatsuo Hosoya; Tetsuya Kawamura

Background: There is no clinical classification of immunoglobulin A nephropathy (IgAN) in clinical practice. In this study, we used receiver-operating characteristic (ROC) analysis to create accurate clinical grades based on clinical parameters associated with the development of end-stage renal disease (ESRD) in IgAN patients. Methods: We performed a retrospective analysis of 116 patients with IgAN. The association between clinical variables and progression to ESRD was examined. Results: Logistic regression analysis indicated that 24-hour urinary protein excretion (UPE) and the estimated glomerular filtration rate (eGFR) at the time of renal biopsy (RBx) were independently associated with the development of ESRD. When combining UPE and eGFR, the areas under the curve were superior to those for UPE or eGFR alone. Moreover, two-graph ROC analysis indicated that the threshold values for UPE and eGFR in predicting future ESRD were 1.0 g/day and 64.0 ml/min/1.73 m2, respectively. Of note, the patients were classified into 4 grades by levels of UPE and/or eGFR, and the OR for risk of ESRD rose significantly from grade I to grade IV. Conclusion: The combination of UPE and eGFR at the time of RBx can improve the predictive accuracy of risk for subsequent ESRD in IgAN patients.


Mutation Research | 1994

Effects of prostaglandin E2 on the micronucleus formation in mouse bone marrow cells by various mutagens

Yuji Suzuki; Hidesuke Shimizu; Tomoharu Ishikawa; Hideyuki Sakaba; Masakatsu Fukumoto; Hideo Okonogi; Makoto Kadokura

The effects of prostaglandin E2 (PGE2), as a trigger of erythroid progenitor cells into the cell cycle, were studied on the induction of micronuclei by various mutagens; with mitomicin C (MMC) the optimal protocol was established. PGE2 itself did not induce any micronuclei in this experiment. The highest frequency of micronuclei and dose-response relationship between PGE2 doses and micronucleus frequency were observed 30 h after injection of MMC to mice administered PGE2 24 h previously. Sensitization by PGE2 pretreatment was also found for other mutagens, such as vincristine, 5-fluorouracil, benzo[a]pyrene, 1,1-dimethylhydrazine and 2-naphthylamine. These results support the hypothesis that accelerating the erythropoiesis increases the frequency of micronuclei induced by mutagens.


Clinical and Experimental Nephrology | 2008

A case of glomerulopathy showing podocytic infolding in association with Sjögren’s syndrome and primary biliary cirrhosis

Kentaro Koike; Yasunori Utsunomiya; Yoriko Ito; Satori Tokudome; Yoichi Miyazaki; Takahide Suzuki; Hideo Okonogi; Tetsuya Kawamura; Akio Yamada; Tatsuo Hosoya; Kensuke Joh

A 49-year-old man was admitted to our hospital with mild proteinuria. Prior to admission, he had been diagnosed as having Sjögren’s syndrome in association with primary biliary cirrhosis. Examination of a renal biopsy under light microscopy revealed diffuse and global mesangial cell proliferation and a spike and/or bubbling formation of the glomerular basement membrane (GBM), resembling membranoproliferative glomerulonephritis. In contrast, immunofluorescent studies showed marked immunoglobulin and complement depositions in the mesangial areas; however, only faint granular IgG and IgA deposition was observed along the GBM. Interestingly, electron microscopy revealed that a microtubular structure, derived from podocytes, was present in the GBM. We present a case of glomerulopathy showing podocytic infolding in association with Sjögren’s syndrome and primary biliary cirrhosis.

Collaboration


Dive into the Hideo Okonogi's collaboration.

Top Co-Authors

Avatar

Tetsuya Kawamura

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Nobuo Tsuboi

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Tatsuo Hosoya

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yoichi Miyazaki

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Makoto Ogura

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yasunori Utsunomiya

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Kentaro Koike

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Keita Hirano

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Takashi Yokoo

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge